Fact CheckerSign in

NCT06811896Recruiting

Adapting a Stress Management Intervention to Reduce Cardiovascular Disease Risk

Adapting and Piloting a Stress Management Intervention to Reduce Cardiovascular Disease Risk Among Women Living With HIV

Source: ClinicalTrials.gov · Last updated 28 Sept 2026

Brief summary (registry, in English)

Women living with HIV have 2-4x higher risk for cardiovascular disease compared to women without HIV, with women living with HIV in the Southern US being particularly at risk. While an increased prevalence of traditional risk factors (e.g., hypertension, diabetes, and obesity) partially explain this risk, evidence suggests that increased exposure to structural and social stressors (e.g., poverty, discrimination, and stigma) among women living with HIV in the South negatively contribute to cardiovascular disease disparities through their impact on stress. The Stress Management and Resiliency Training (SMART) program is an effective, evidence-based intervention proven to improve resiliency to environmental stressors and reduce the physiologic responses to stress which contribute to cardiovascular disease. While the SMART program has demonstrated efficacy in a wide range of populations and settings, it has not been designed for or tested among women living with HIV in the South, where unique cultural and faith-based context may diminish the uptake and value of the intervention to mitigate cardiovascular disease risk. The purpose of this study is to adapt the evidence-based SMART program in consideration of the needs and contexts of women living with HIV in the Southern US and pilot the adapted intervention to establish the feasibility, acceptability, and preliminary impact of the adapted intervention to reduce stress and mitigate cardiovascular disease risk among this population.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
48 (estimated)
First submitted
31 Jan 2025
Start date
14 May 2025
Primary completion date
Apr 2027
Lead sponsor
University of Alabama at Birmingham
Diseases
HIV
NCT number
NCT06811896

What you commit to

  • Study type: Interventional
  • Planned participants: 48
  • From 14 May 2025 to the primary completion date, Apr 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • severe mental illness

Other

  • not being willing able to provide informed consent
  • not willing or able to attend study visits

Who the study is looking for

  • cis-gender females at least 18 years of age
  • HIV-seropositive and a patient of the recruiting clinic
  • English speaking

Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Alabama at Birmingham
Coordinator of this site? Confirm its status
BirminghamUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.